Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Formulation dissolution testing

Blending Formulations Dissolution testing Drying Tableting... [Pg.544]

Figure 4.50. Cumulative dissolution results. Two experimental tablet formulations were tested against each other in a dissolution test in which tablets are immersed in a stirred aqueous medium (number of tablets, constructional details and operation of apparatus, and amount of medium are givens). Eighty or more percent of the drug in either formulation is set free within 10 minutes. The slow terminal release displayed by formulation B could point towards an unwanted drug/excipient interaction. The vertical bars indicate ymean - with Sy 3%. A simple linear/exponential model was used to approximate the data for the strength 2 formulation. Strengths I and 3 are not depicted but look very similar. Figure 4.50. Cumulative dissolution results. Two experimental tablet formulations were tested against each other in a dissolution test in which tablets are immersed in a stirred aqueous medium (number of tablets, constructional details and operation of apparatus, and amount of medium are givens). Eighty or more percent of the drug in either formulation is set free within 10 minutes. The slow terminal release displayed by formulation B could point towards an unwanted drug/excipient interaction. The vertical bars indicate ymean - with Sy 3%. A simple linear/exponential model was used to approximate the data for the strength 2 formulation. Strengths I and 3 are not depicted but look very similar.
It is interesting that the in vitro dissolution test (USP) was more sensitive to the piroxicam formulation variables than the biodata. The fast, moderate, and slow products were found bioequivalent to each other and to the lot of innovator product studied [100]. It is possible that either the formulation variables studied did not affect in vivo dissolution and/or the differences were not discernible because of the long biological half-life of piroxicam [146]. [Pg.374]

Extensions of BCS beyond the oral IR area has also been suggested, for example to apply BCS in the extended-release area. However, this will provide a major challenge since the release from different formulations will interact in different ways with in vitro test conditions and the physiological milieu in the gastrointestinal tract. For example, the plasma concentration-time profile differed for two felodipine ER tablets for which very similar in vitro profiles had been obtained, despite the fact that both tablets were of the hydrophilic matrix type based on cellulose derivates [70], This misleading result in vitro was due to interactions between the gel strength of the matrix and components in the dissolution test medium of no in vivo relevance. The situation for ER formulations would be further complicated by the need to predict potential food effects on the drug release in vivo. [Pg.516]

The BCS could be used as a framework for predictions when IVIVC could be expected for solid IR products, as summarized in Table 21.5. It is important to realize that the in vitro dissolution test only models the release and dissolution of the active drug substance from the formulation, and it is only when these processes are rate-limiting in the absorption process that IVIVC can be expected. In... [Pg.520]

Ritonavir is a product of Abbott Laboratories Ltd. for the treatment of HIV and is marketed as Norvir , in liquid and semisolid capsule formulations. It received FDA approval for market launch in march 1996, at which time only one polymorphic form of Ritonavir (Form I) was known. Two years later in early 1998 a laboratory responsible for testing the formulated product in the US reported dissolution test failures of the semisolid capsules, and noted that drug product had precipitated out of solution. A new polymorphic form had been discovered that was thermodynamically more stable than the existing form and approximately 5 times less soluble in the formulation. Figure 7. [Pg.42]

It should be remembered that in 1970, when drug-release/dissolution tests first became official through the leadership of USP and NF, marketed tablets or capsules in general simply did not have a defined dissolution character. They were not formulated to achieve a particular dissolution performance, nor were they subjected to quality control by means of dissolution testing. Moreover, the U.S. Food and Drug Administration (FDA) was not prepared to enforce dissolution requirements or to even to judge their value. [Pg.10]

When performing dissolution testing, there are many ways that the test may generate erroneous results. The testing equipment and its environment, handling of the sample, formulation, in situ reactions, automation and analytical techniques can all be the cause of errors and variability. The physical dissolution of the dosage form should be unencumbered at all times. Certain aspects of the equipment calibration process may show these errors as well as close visual observation of the test. The essentials of the test are accuracy of results and robustness of the method. Aberrant and unexpected results do occur, however, and the analyst should be well trained to examine all aspects of the dissolution test and observe the equipment in operation. [Pg.58]

The desire of USP experts for contributed dissolution procedures for most official immediate-release solid oral dosage forms was not fulfilled. In 1980, a policy giving a framework for the comprehensive application of a dissolution test procedure was formulated. The policy recognized three classes of products for which the dissolution test could be applied with increasing brand-linked specificity. First Case conditions were intended for the most general class where either the basket at 100 rpm or the paddle at 50 rpm was... [Pg.74]

Over the last quarter century the dissolution test has emerged as a most powerful and valuable tool to guide formulation development, monitor the manufacturing process, assess product quality, and in some cases to predict in vivo performance of solid oral dosage forms. Under certain conditions, the dissolution test can be used as a surrogate measure for bioequivalence (BE) and to provide biowaivers, assuring BE of the product. Dissolution test has turned out to be a... [Pg.81]

Choice of Dissolution Tests to Compare Formulations During Development... [Pg.200]


See other pages where Formulation dissolution testing is mentioned: [Pg.452]    [Pg.908]    [Pg.346]    [Pg.452]    [Pg.908]    [Pg.346]    [Pg.199]    [Pg.207]    [Pg.208]    [Pg.514]    [Pg.515]    [Pg.517]    [Pg.522]    [Pg.526]    [Pg.315]    [Pg.251]    [Pg.259]    [Pg.266]    [Pg.271]    [Pg.43]    [Pg.8]    [Pg.11]    [Pg.11]    [Pg.12]    [Pg.14]    [Pg.15]    [Pg.31]    [Pg.32]    [Pg.33]    [Pg.84]    [Pg.84]    [Pg.87]    [Pg.89]    [Pg.94]    [Pg.118]    [Pg.128]    [Pg.156]    [Pg.157]    [Pg.182]    [Pg.194]    [Pg.194]    [Pg.196]    [Pg.199]   
See also in sourсe #XX -- [ Pg.482 ]




SEARCH



Dissolution test, formulations

Dissolution test, formulations

Dissolution testing

Dissolution testing formulation support

Tablet formulations dissolution test methods

© 2024 chempedia.info